National Cancer Institute, France

• Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.

  Collaborator, Phase 1/2, Not yet recruiting, 89 people, 1 Oct 2026

• NCT05986071

  Collaborator, Phase 1/2, Not yet recruiting, 57 people, 14 Aug 2023

• NCT05615818

  Collaborator, Phase 3, Recruiting, 800 people, 14 Nov 2022

• Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features

  Collaborator, Phase 3, Recruiting, 316 people, 24 Feb 2022

• NCT04945148

  Collaborator, Phase 2, Recruiting, 640 people, 30 Jun 2021

• NCT04747054

  Collaborator, Phase 3, Recruiting, 102 people, 10 Feb 2021

• NCT04446962

  Collaborator, Phase 1/2, Active, not recruiting, 118 people, 25 Jun 2020

• NCT04325425

  Collaborator, Phase 2, Recruiting, 218 people, 27 Mar 2020

• NCT04116502

  Collaborator, Phase 3, Recruiting, 586 people, 4 Oct 2019

• NCT03819101

  Collaborator, Phase 3, Recruiting, 1,210 people, 28 Jan 2019

• NCT03774732

  Collaborator, Phase 3, Active, not recruiting, 327 people, 13 Dec 2018

• NCT03351296

  Collaborator, Phase 2, Active, not recruiting, 140 people, 22 Nov 2017

• NCT02998385

  Collaborator, Phase 3, Active, not recruiting, 342 people, 20 Dec 2016

• NCT02845999

  Collaborator, Phase 1, Completed, 9 people, 27 Jul 2016

• NCT02813135

  Collaborator, Phase 1/2, Recruiting, 472 people, 24 Jun 2016

• NCT02724163

  Collaborator, Phase 3, Active, not recruiting, 700 people, 31 Mar 2016

• NCT02515877

  Collaborator, Phase 1, Completed, 15 people, 5 Aug 2015

• NCT02501213

  Collaborator, Phase 2, Terminated, 14 people, 17 Jul 2015

• NCT02494973

  Collaborator, Phase 2/3, Completed, 104 people, 10 Jul 2015

• NCT02359968

  Collaborator, Phase 2, Completed, 106 people, 10 Feb 2015

Sources: clinicaltrials.gov